Skip to content

Pulmonary Rehabilitation in Idiopathic Pulmonary Fibrosis

Short and Long-term Effects of Oxygen Supplemented Pulmonary Rehabilitation in Idiopathic Pulmonary Fibrosis

Status
Completed
Phases
NA
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT03326089
Enrollment
20
Registered
2017-10-30
Start date
2017-06-01
Completion date
2023-08-28
Last updated
2023-08-30

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Idiopathic Pulmonary Fibrosis

Keywords

pulmonary rehabilitation

Brief summary

This is an interventional double-blind randomized controlled trial, to investigate the short and long-term effects of a supervised exercise training program in patients with IPF, depending on alternate patterns of oxygen supplementation during PR.

Detailed description

The investigators hypothesize that PR service with supplemented oxygen supply regardless of hypoxemia may have significantly better short-term effects in patients with IPF. The study will take place in Corfu General Hospital, by the Departments of Pulmonary Medicine and Physiotherapy and Rehabilitation, respectively. Study participants will be divided in two equal arms 1:1 in a double-blind manner. One of the investigators blinded to their clinical data will assign each participant to PR service either i) with constant supplementary oxygen supply FiO2 50% regardless of saturation status Group A) or ii) without oxygen supply unless upon resting or exercise induced hypoxemia (saturation \<88%) (Group B).

Interventions

PROCEDUREPulmonary rehabilitation

Endurance training for 30 minutes, 3 times/week for 2 months followed by resistance training

Sponsors

Corfu General Hospital
Lead SponsorOTHER

Study design

Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
DOUBLE (Subject, Investigator)

Masking description

participants are blindly randomized to receive oxygen or not during rehabilitation.

Eligibility

Sex/Gender
ALL
Healthy volunteers
No

Inclusion criteria

* diagnosis of IPF based on current established criteria * no exacerbation previous 3 months * no participation in such program previous 3 months. * If on treatment with pirfenidone or nintedanib, this will be recorded and patient should be on treatment for at least 3-6 months to achieve stable state.

Exclusion criteria

\- concomitant diagnosis of congestive heart failure and lung cancer.

Design outcomes

Primary

MeasureTime frameDescription
6 Minute Walk Test Distance (6MWTD) (meters)2 monthsStatistically significant short term effect on exercise capacity
Saint-George Respiratory Questionnaire Idiopathic Pulmonary Fibrosis Version (SGRQ-I) (units on scale)2 monthsStatistically significant short term effect on health related quality of life
Hospital Anxiety and Depression Scale (HADS) (units on scale)2 monthsStatistically significant short term effect on health related quality of life

Secondary

MeasureTime frameDescription
6 Minute Walk Test Distance (6MWTD) (meters)12 monthsStatistically significant long term effect on exercise capacity
Saint-George Respiratory Questionnaire Idiopathic Pulmonary Fibrosis Version (SGRQ-I) (units on scale)12 monthsStatistically significant long term effect on health related quality of life
Hospital Anxiety and Depression Scale (HADS) (units on scale)12 monthsStatistically significant long term effect on health related quality of life

Countries

Greece

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026